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Abstract
A rare case is presented of a 61-year-old man with a malignant peripheral nerve sheath tumor associated with
neurofibromatosis type 1, with metastasis to the heart. The primary tumor originated in the right thigh in 1982.
Since then, the patient has had repeated local recurrences in spite of repeated surgical treatment and adjuvant
chemotherapy. He has developed previous metastases of the lung and heart. The patient died of cardiac
involvement.
Background
Malignant peripheral nerve sheath tumor (MPNST) is
an aggressive and uncommon neoplasm that develops
within a peripheral nerve; most cases of which are asso-
ciated with neurofibromatosis type 1 (NF1). Metastasis
of MPNST usually occurs in the lung [1], whereas car-
diac metastasis of MPNST is quite rare [2-4]. In this
report, we describe a case of MPNST that metastasized
to the heart, with a review of the literature.
Case Presentation
A 61-year-old man presented with clinical stigmata of
NF1. Genetic analysis had not been performed. He had
no family history and had developed multiple neurofi-
bromas and café-au-lait spots on his body (Figure 1). He
underwent surgical treatment for a growing tumor
(details are unknown) on the posterior surface of his
right thigh at another hospital in April 1982, and was
referred to our institution because of regrowth of the
tumor in October 1990. Wide resection was performed
in November 1990 (Figure 2). The histological diagnosis
was MPNST developed on a background of NF1, and he
received adjuvant chemotherapy. Since 1990, the patient
has had repeated local recurrences (7 times, until May
2003) and has received surgical treatment for each
recurrent tumor. In December 2003, the patient pre-
sented with a skin tumor of the head, and the lesion
was resected. The histological diagnosis was MPNST
that arose in a neurofibroma of the head skin. Two
years later, the right leg was amputated at the hip joint
because of local recurrence of the leg lesion, with
aggressive growth and rupture. Computed tomography
(CT) performed in August 2005 showed multiple lung
lesions, suggestive of tumor metastases. Some of the
lung lesions were resected surgically in January 2006
and diagnosed histologically as MPNST metastases.
After the operation, he developed new lung metastases.
In May 2007, he was admitted to our institution with
sudden dyspnea and palpitations. Echocardiography
revealed an enlarged heart and cardiac effusion, which
did not suggest cardiac tamponade. Magnetic resonance
imaging showed the presence of a large tumor (9 cm) in
the inferior-posterior wall of the heart (Figure 3). CT
revealed an infarction of the inferior lobe of the left
lung, which was derived from tumor emboli. As a result
of the worsening condition, irradiation was applied to
the cardiac mass (2 × 25 Gy). The patient’s condition
still worsened, with increasing cardiac effusion and
arrhythmia. Regardless of drainage of the effusion, he
died of acute heart failure soon after. At autopsy, the
cardiac mass was confirmed histologically as MPNST
(Figure 4). The cardiac lesion was thought to be a meta-
static tumor, because neurofibroma was not seen as
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gested that the tumor involved the conduction system.
MPNST affected both lungs. Histological images of car-
diac and pulmonary tumor were similar to those of the
tumor of the right leg that was amputated in 2005 (Fig-
ure 2).
Discussion
Patients with NF are at greatest risk for developing sar-
comas, including MPNST. The incidence of MPNST
arising in NF is 4.6%, which is much higher than the
0.001% in general population [5]. The most common
metastatic site of MPNST is the lung [1,4]. Cardiac
involvement from metastatic MPNST is extremely rare,
whether with or without a background of NF [2-4]. Our
patient is one of the extremely rare cases of cardiac
metastasis of MPNST associated with NF1. Most of the
cardiac metastases are preceded by other metastatic
lesions, such as in the lung. Although the possibility of
cardiac involvement becomes higher as the tumor pro-
gresses, details of the histopathological features specific
to cardiac metastasis remain to be investigated. Recent
studies have in part revealed the genomic imbalance in
sporadic and NF1-associated MPNST [6,7]. The biology
Figure 1 Clinical manifestations of NF1: multiple cutaneous neurofibromas and café-au-lait spots.
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Page 2 of 6Figure 2 Hematoxylin and eosin and S-100 staining of the tumors of the thigh treated surgically in 1990 (A, B), recurrent tumor
operated in 1995 (C, D) and metastatic tumor in heart (E, F) and lung (G, H) at autopsy in 2007. A, C, E, G: Hematoxylin and eosin
staining; B, D, F, H: S-100 immunohistochemistry. Histological factors such as cellularity, degree of nuclear atypia, mitotic counts, and S-100
immunoreactivity were similar among the specimens.
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unknown.
The prognosis of patients with MPNST is generally
poor. Aggressive surgery significantly improved disease-
free survival [5,8]. Adjuvant chemotherapy and radiother-
apy has not been proven to prolong patient survival, but
it is effective as a palliative option [4,8,9]. If clinical
symptoms of cardiac dysfunction occur during the pro-
gression of MPNST, it might be that the heart is
involved. In such cases of MPNST, it is necessary to
exclude cardiac involvement, even if it is rare, by occa-
sional echocardiography. Early diagnosis can allow timely
surgical intervention, if the patient is operable, which
may improve results, as in the case described here.
Clinical features vary according to the site of cardiac
involvement[10], such as pericardium, epicardium,
myocardium or endocardium. The present case showed
a large mass in the myocardial region, which was
accompanied with increasing pericardial effusion and
arrhythmia. Serial histological sections revealed that the
metastatic tumor markedly affected the common bundle
of His, in addition to the ordinary myocardium. Based
on these findings, we surmised that complete atrioven-
tricular block was attributable to cardiac metastasis of
MPNST, which is causative of circulatory failure [10].
Related features of cardiac involvement of MPNST are
uncertain. More cases should be reported to elucidate
the clinical entity associated with cardiac involvement of
M P N S Ta n dt of o r m u l a t ea na p p r o p r i a t et r e a t m e n t
strategy.
Most NF1 patients carry a constitutional mutation of
the NF1 tumor suppressor gene [11]. Biallelic
Figure 3 Magnetic resonance imaging showed a large tumor in the inferior-posterior wall of the heart. (A) Frontal cross section. Size: 7.5
cm. (B) Horizontal cross section. Size: 9 cm. (C) Sagittal cross section. Size: 6.5 cm.
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tional tumor suppressor genes within the p19
ARF-
MDM2-TP53 and p16
INK4A-Rb signaling cascades have
been identified in MPNSTs [12,13]. These abnormalities
of suppressor genes, except for NF1, are not present in
neurofibromas. It is therefore thought that the develop-
ment of neurofibromas and their subsequent progres-
sion to become MPNSTs involves a sequential series of
tumor suppressor mutations. Deletions and other muta-
t i o n st h a tr e s u l ti nl o s so ff u n c t i o no ft h eTP53 tumor
suppressor gene are some of the more common
abnormalities found in MPNSTs. Biallelic inactivation of
the TP53 locus is found rarely in MPNST, which has
led to the suggestion that hemizygous TP53 mutations
may suffice for neurofibromas to progress and become
MPNSTs.
Figure 4 Autopsy specimen showing a tumor in the heart.
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cell lines derived from sporadically occurring MPNSTs
have functional and intact NF1 genes [14]. Paradoxically,
however, microarray studies that have compared the
transcriptomes of sporadic and NF1-associated MPNSTs
have not found a molecular signature that distinguishes
these neoplasms [14,15].
For understanding of these complex neoplasms and
the development of the effective new therapy, further
investigation will be needed into the clinical features
and the basic science.
Conclusion
Although cardiac involvement of MPNST is rare, precise
examination including occasional echocardiography is
necessary when clinical signs of tumor development in
the heart are suspected.
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